Hypogammaglobulinemia clinical trials

Explore recruiting hypogammaglobulinemia clinical trials.

Recruiting hypogammaglobulinemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypogammaglobulinemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")

Czechia, Lithuania, Greece, Poland, Germany, Latvia +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The MEMORINEPH study: Memory B cell level-based tailored treatment with Rixathon in children with complicated forms of steroid-sensitive Nephrotic syndrome

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutaneous belimumab versus rituximab + placebo in adult patients with persistent or chronic immune thrombocytopenia (ITP)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease

Germany, Austria, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Anti-CD19 CAR T-Cell TherApy in Refractory Systemic Autoimmune DISeases - CATARSIS

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Romania, Poland, Hungary, Bulgaria, Croatia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hypogammaglobulinemia trials by city

Hypogammaglobulinemia in Toronto Hypogammaglobulinemia in Vancouver Hypogammaglobulinemia in Montreal Hypogammaglobulinemia in Calgary Hypogammaglobulinemia in Edmonton Hypogammaglobulinemia in Ottawa Hypogammaglobulinemia in Winnipeg Hypogammaglobulinemia in Quebec City Hypogammaglobulinemia in Hamilton Hypogammaglobulinemia in Kitchener Hypogammaglobulinemia in London Hypogammaglobulinemia in Halifax Hypogammaglobulinemia in New York Hypogammaglobulinemia in Los Angeles Hypogammaglobulinemia in Chicago Hypogammaglobulinemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease